176 related articles for article (PubMed ID: 32409702)
1. Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC.
Gu J; Zhang Y; Han Z; Gao L; Cui J; Sun Y; Niu Y; You B; Huang CP; Chang C; Wang X; Yeh S
Cell Death Dis; 2020 May; 11(5):367. PubMed ID: 32409702
[TBL] [Abstract][Full Text] [Related]
2. Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
Song W; He D; Chen Y; Yeh CR; Hsu I; Huang Q; Zhang X; Chang LS; Zuo L; Chen J; Doersch KM; Chang C; Li L; Yeh S
Mol Oncol; 2018 Dec; 12(12):2055-2071. PubMed ID: 30171816
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling.
He M; Yang H; Shi H; Hu Y; Chang C; Liu S; Yeh S
Cancer Lett; 2022 Jan; 524():15-28. PubMed ID: 34461182
[TBL] [Abstract][Full Text] [Related]
4. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation.
Yu CP; Ho JY; Huang YT; Cha TL; Sun GH; Yu DS; Chang FW; Chen SP; Hsu RJ
PLoS One; 2013; 8(2):e56667. PubMed ID: 23460808
[TBL] [Abstract][Full Text] [Related]
5. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
6. ERβ-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma.
Han Z; Zhang Y; Sun Y; Chen J; Chang C; Wang X; Yeh S
Cancer Res; 2018 May; 78(10):2550-2563. PubMed ID: 29490945
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor beta increases clear cell renal cell carcinoma stem cell phenotype via altering the circPHACTR4/miR-34b-5p/c-Myc signaling.
Wang Y; Yang Z; Gu J; Zhang Y; Wang X; Teng Z; Wang D; Gao L; Li W; Yeh S; Han Z
FASEB J; 2022 Feb; 36(2):e22163. PubMed ID: 35061326
[TBL] [Abstract][Full Text] [Related]
8. Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor β-DAB2IP signals.
Yeh CR; Ou ZY; Xiao GQ; Guancial E; Yeh S
Oncotarget; 2015 Dec; 6(42):44346-59. PubMed ID: 26587829
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
10. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Wang M; Sun Y; Xu J; Lu J; Wang K; Yang DR; Yang G; Li G; Chang C
Int J Cancer; 2018 Jul; 143(1):100-112. PubMed ID: 29396852
[TBL] [Abstract][Full Text] [Related]
11. Silencing Estrogen Receptor-β with siRNA in Cultured Cells.
Hsu RJ; Liu JM
Methods Mol Biol; 2016; 1366():353-358. PubMed ID: 26585149
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
13. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
14. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
[TBL] [Abstract][Full Text] [Related]
15. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network.
Ding J; Yeh CR; Sun Y; Lin C; Chou J; Ou Z; Chang C; Qi J; Yeh S
Oncogene; 2018 Sep; 37(37):5037-5053. PubMed ID: 29789714
[TBL] [Abstract][Full Text] [Related]
17. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
18. ZDHHC2-Mediated AGK Palmitoylation Activates AKT-mTOR Signaling to Reduce Sunitinib Sensitivity in Renal Cell Carcinoma.
Sun Y; Zhu L; Liu P; Zhang H; Guo F; Jin X
Cancer Res; 2023 Jun; 83(12):2034-2051. PubMed ID: 37078777
[TBL] [Abstract][Full Text] [Related]
19. G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma.
Chen SK; Wang YC; Lin TY; Wu HJ; Huang CJ; Ku WC
Cancer Genomics Proteomics; 2021; 18(3):207-220. PubMed ID: 33893075
[TBL] [Abstract][Full Text] [Related]
20. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
